MARKET

DGNOF

DGNOF

Diagnos Inc
OTCMQB
0.146
-0.004
-2.66%
Closed 10:40 06/09 EDT
OPEN
0.146
PREV CLOSE
0.150
HIGH
0.146
LOW
0.146
VOLUME
11.00K
TURNOVER
1.61K
52 WEEK HIGH
0.288
52 WEEK LOW
0.133
MARKET CAP
17.59M
P/E (TTM)
-4.4543
1D
5D
1M
3M
1Y
5Y
1D
Diagnos targets June 10 Health Canada submission for next-generation CARA AI platform
PUBT · 4d ago
Emerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI Platform
Barchart · 5d ago
Diagnos CEO Larente to present at Emerging Growth Conference
PUBT · 6d ago
Diagnos extends maturity on CAD 300,000 convertible debentures to May 2027
PUBT · 05/13 23:00
DIAGNOS ANNOUNCES AMENDMENT TO CONVERTIBLE DEBENTURES
Reuters · 05/13 23:00
Diagnos targets Health Canada submission for new CARA in May, FDA filing by Q3-end
Reuters · 04/08 16:20
DIAGNOS INC - REMAINS ENGAGED IN SAUDI FOOD AND DRUG AUTHORITY REVIEW PROCESS FOR CARA
Reuters · 04/08 16:14
Diagnos completes annual US FDA medical device facility registration renewal
Reuters · 04/01 16:02
More
About DGNOF
Diagnos Inc. is a Canadian company, which is engaged in the early detection of critical eye-related health problems using advanced technology based on Artificial Intelligence (AI). It markets Computer Assisted Retinal Analysis (CARA), a software platform which assists health specialists in the detection of certain retinopathy pathologies through the computerized analysis of retina images. CARA is an in-house-hosted Web-based application that integrates fundus cameras with an image processing engine over a secure Internet connection. The CARA suite of applications allows an eye care specialist to more clearly visualize both normal retinal landmarks (optic nerve, vascular system, macula, fovea), and pathological changes (exudates, haemorrhages, micro-aneurisms, neo-vascularization). CARA is indicated for use by healthcare professionals in an adult general population in the context of a general eye-health exam.

Webull offers Diagnos Inc stock information, including OTCMQB: DGNOF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DGNOF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DGNOF stock methods without spending real money on the virtual paper trading platform.